Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1989-5-31
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0091-2700
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
29
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1-6
|
pubmed:dateRevised |
2000-12-18
|
pubmed:meshHeading |
pubmed-meshheading:2708544-Drug Industry,
pubmed-meshheading:2708544-Legislation, Drug,
pubmed-meshheading:2708544-Pharmacokinetics,
pubmed-meshheading:2708544-Population,
pubmed-meshheading:2708544-Research Design,
pubmed-meshheading:2708544-United States,
pubmed-meshheading:2708544-United States Food and Drug Administration
|
pubmed:year |
1989
|
pubmed:articleTitle |
Controversy. IV: Population pharmacokinetics, NONMEM and the pharmacokinetic screen; academic, industrial and regulatory perspectives.
|
pubmed:publicationType |
Journal Article
|